RecruitingPhase 2NCT07284459

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Sponsor

Contineum Therapeutics

Enrollment

324 participants

Start Date

Jan 8, 2026

Study Type

INTERVENTIONAL

Conditions

Idiopathic Pulmonary Fibrosis

Summary

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.

Eligibility

Min Age: 40 Years

Inclusion Criteria4

Male or female ≥ 40 years of age at the time of Randomization
A diagnosis of IPF within 7 years prior to Screening, based on the 2018 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT with verification of usual interstitial pneumonia
Percent predicted (pp) FVC ≥ 40% on Screening spirometry
Subjects may enter the study whether or not they are receiving background antifibrotic therapy, approved for the treatment of IPF (nintedanib or pirfenidone, but not both concurrently)

Exclusion Criteria4

Those with a history of interstitial lung disease (ILD) other than IPF are not eligible.
Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible.
Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible.
Those with an estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula) (Inker 2021) or who have Child-Pugh Class B or C hepatic impairment are not eligible.

Interested in this trial?

Get notified about updates and connect with the research team.